Baxter(US:BAX) Globenewswireยท2025-10-23 15:52Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed systemic defects in its Novum IQ Large Volume Pump, which have resulted in serious risks to patients and significant stock price decline [3][4]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. - The lawsuit claims that Baxter's Novum IQ LVP suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures, which continued to expose patients to harm [3]. Group 2: Impact on Company Operations - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, unable to provide a timeline for resuming operations [4]. - The company suggested an alternative product, the Spectrum infusion pump, to customers while indicating that its low-end guidance assumes no resumption of Novum LVP shipments before year-end [4]. - Following the announcement, Baxter's stock price dropped by more than 22%, reflecting investor concerns over the ongoing issues with the Novum LVP [4].